First introduced in the mid-1990s through the pioneering work of BC-CfE Executive Director and Physician-in-Chief Dr. Julio Montaner, combination antiretroviral therapy (cART) is a pillar of the Treatment as Prevention®¨ strategy that has enabled people living with HIV to live longer and healthier lives and has dramatically reduced the risk of HIV transmission.
The BC-CfE continues to lead the way in COVID-19 research, with the latest published research on the topic coming from the Centre’s Molecular Epidemiology and Evolutionary Genetics Group.
The paper, which features contributions from almost all members of the group, focuses on evolutionary patterns among coronaviruses that have jumped from animal hosts into humans and is titled “Variable routes to genomic and host adaptation among coronaviruses“.
UN Women is the United Nations entity dedicated to gender equality and the empowerment of women. UN Women has announced the theme for International Women’s Day 2021 as,”Women in leadership: Achieving an equal future in a COVID-19 world.”
BC-CfE researchers are working alongside colleagues from the University of British Columbia, Providence Health Care, and Simon Fraser University to investigate how elderly peoples’ immune systems respond to COVID-19 vaccines. The researchers will also assess the viral, immunological and social factors that have contributed to COVID-19 outbreaks in long-term care facilities in order to better understand why and how the disease has been fatal to so many residents.
Thanks to the introduction of highly active antiretroviral therapy (HAART) in the 1990s and the BC-CfE’s Treatment as Prevention®¨ strategy, people living with HIV (PLWH) in BC are now able to live longer lives. With an increased lifespan, morbidity and mortality from non-AIDS comorbidities have emerged as major concerns.
Terry Salman, a friend and long-time supporter of the BC-CfE, was recently named a member of the Order of Canada.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
